Black Rock Inc. Biohaven Pharmaceutical Holding CO Ltd. Transaction History

Black Rock Inc.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$144.95 - $152.29 $17.7 Million - $18.6 Million	-122,158 Reduced 2.41%	4,949,917 $748 Million
Q2 2022 Aug 12, 2022	BUY	$83.14 - $145.99 $34.5 Million - $60.6 Million	415,209 Added 8.92%	5,072,075 $739 Million
Q1 2022 May 12, 2022	BUY	$110.08 - $142.92 $2.38 Million - $3.09 Million	21,586 Added 0.47%	4,656,866 $552 Million
Q4 2021 Feb 10, 2022	BUY	$99.73 - $148.48 $2.81 Million - $4.19 Million	28,207 Added 0.61%	4,635,280 $639 Million
Q3 2021 Nov 09, 2021	SELL	$98.85 - $138.91 $8.35 Million - $11.7 Million	-84,505 Reduced 1.8%	4,607,073 $640 Million
Q2 2021 Aug 11, 2021	BUY	$65.78 - $105.02 $309 Million - $493 Million	4,691,578 New	4,691,578 $455 Million

785K

Ticker BHVN
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,645,000
Market Cap $3.65B
Description
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavege...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.